# ![@Biomeainvestors Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1986473881507684352.png) @Biomeainvestors Biomea Investors

Biomea Investors posts on X about $bmea, watch, ama, advance the most. They currently have [--] followers and [--] posts still getting attention that total [--] engagements in the last [--] hours.

### Engagements: [--] [#](/creator/twitter::1986473881507684352/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1986473881507684352/c:line/m:interactions.svg)

- [--] Week [---] -31%
- [--] Month [-----] +395%

### Mentions: [--] [#](/creator/twitter::1986473881507684352/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1986473881507684352/c:line/m:posts_active.svg)


### Followers: [--] [#](/creator/twitter::1986473881507684352/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1986473881507684352/c:line/m:followers.svg)

- [--] Week [--] +4.20%
- [--] Month [--] +32%

### CreatorRank: undefined [#](/creator/twitter::1986473881507684352/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1986473881507684352/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  96.43% [financial services](/list/financial-services)  14.29% [finance](/list/finance)  3.57%

**Social topic influence**
[$bmea](/topic/$bmea) #5, [watch](/topic/watch) 10.71%, [ama](/topic/ama) 7.14%, [advance](/topic/advance) 7.14%, [ceo](/topic/ceo) 7.14%, [core](/topic/core) 3.57%, [resistance](/topic/resistance) 3.57%, [more than](/topic/more-than) 3.57%, [strong](/topic/strong) 3.57%, [sector](/topic/sector) 3.57%

**Top assets mentioned**
[Biomea Fusion, Inc. (BMEA)](/topic/$bmea)
### Top Social Posts
Top posts by engagements in the last [--] hours

"$BMEA At WCIRDC [----] a core idea was revisited: Type [--] diabetes often involves two challenges at the same time. Reduced insulin production and reduced response to insulin. Over time insulin resistance places stress on beta cells contributing to beta cell dysfunction and loss"  
[X Link](https://x.com/Biomeainvestors/status/2001689007873241231)  2025-12-18T16:20Z [--] followers, [---] engagements


"$BMEA Within this framework Biomea Fusion highlighted menin inhibition as an approach to support beta cell recovery by easing a natural limit on beta cell growth. The session also noted the importance of addressing insulin sensitivity alongside beta cell restoration"  
[X Link](https://x.com/Biomeainvestors/status/2001689010461380620)  2025-12-18T16:20Z [--] followers, [---] engagements


"$BMEA At WCIRDC [----] experts highlighted a subgroup of people with type [--] diabetes driven by loss of insulin producing beta cells. Biomea Fusions work on menin inhibition was discussed as a way to support beta cell recovery. Share your questions for our upcoming AMA"  
[X Link](https://x.com/Biomeainvestors/status/2003917255990792413)  2025-12-24T19:54Z [--] followers, [---] engagements


"At WCIRDC [----] a key point was that Type [--] diabetes is driven by more than one biological factor. Restoring beta-cell function matters but durable outcomes also depend on improving insulin response. This biology-driven view underpins $BMEA approach. https://youtu.be/hjhRXMKmhzYsi=Cmdnz94bGsNIt6_E https://youtu.be/hjhRXMKmhzYsi=Cmdnz94bGsNIt6_E"  
[X Link](https://x.com/Biomeainvestors/status/2005364441555357865)  2025-12-28T19:45Z [--] followers, [---] engagements


"$BMEA As industry analysts look toward [----] several themes are emerging that may shape the biotech landscape. Commentary increasingly points to companies with clear clinical paths strong scientific data and execution driven strategies"  
[X Link](https://x.com/Biomeainvestors/status/2008294314917470645)  2026-01-05T21:47Z [--] followers, [---] engagements


"$BMEA [----] is expected to be an important inflection year as programs advance key datasets emerge and regulatory pathways become clearer across the biotech sector"  
[X Link](https://x.com/Biomeainvestors/status/2008294317236850725)  2026-01-05T21:47Z [--] followers, [---] engagements


"For $BMEA [----] will be defined by execution across planned programs: advancing icovamenib through Phase II in insulin deficient T2D and not controlled on GLP [--] completing BMF [---] Phase I and progressing preclinical work in Type [--] diabetes and obesity"  
[X Link](https://x.com/Biomeainvestors/status/2008294319753474050)  2026-01-05T21:47Z [--] followers, [---] engagements


"$BMEA [----] marked substantial progress for Biomea Fusion across clinical development corporate strategy and investor engagement. Throughout the year the company delivered on key priorities that supported its mission to advance innovative oral therapies for metabolic disease"  
[X Link](https://x.com/Biomeainvestors/status/2009091239409561833)  2026-01-08T02:34Z [--] followers, [---] engagements


"$BMEA As we close [----] the continuity of our clinical programs and disciplined execution position Biomea for progress in [----]. Icovamenib Phase II data showed durable glycemic control and C-peptide improvements supporting its potential in insulin-deficient Type [--] diabetes"  
[X Link](https://x.com/Biomeainvestors/status/2009091243142479956)  2026-01-08T02:34Z [--] followers, [---] engagements


"$BMEA Biomea Fusion is presenting today at the 44th Annual J.P. Morgan Healthcare Conference. The presentation includes updates on the Companys metabolic disease programs and clinical development strategy. Register for the live webcast https://jpmorgan.metameetings.net/events/healthcare26/sessions/317408-biomea-fusion-inc/webcast/general_signingpu_only=true&kiosk=true https://jpmorgan.metameetings.net/events/healthcare26/sessions/317408-biomea-fusion-inc/webcast/general_signingpu_only=true&kiosk=true"  
[X Link](https://x.com/Biomeainvestors/status/2011459831560106015)  2026-01-14T15:26Z [--] followers, [---] engagements


"$BMEA participated in the 44th Annual J.P. Morgan Healthcare Conference. We thank J.P. Morgan for hosting one of the leading global forums for healthcare and biotech investors. Follow along for key updates"  
[X Link](https://x.com/Biomeainvestors/status/2013026364136288398)  2026-01-18T23:11Z [--] followers, [---] engagements


"$BMEA During the conference Interim CEO Mick Hitchcock Ph.D. shared updates on icovamenib advancing toward Phase II in diabetes and the ongoing Phase I of BMF-650 in obesity. We remain focused on disciplined execution and transparency. Stay engaged"  
[X Link](https://x.com/Biomeainvestors/status/2013026367630188851)  2026-01-18T23:11Z [--] followers, [---] engagements


"$BMEA At the J.P. Morgan Healthcare Conference Interim CEO Mick Hitchcock highlighted icovamenib our lead oral therapy for type [--] diabetes. The program is advancing toward Phase II with first patient enrollment expected in 1Q26. We remain focused on disciplined execution"  
[X Link](https://x.com/Biomeainvestors/status/2013605960040800388)  2026-01-20T13:34Z [--] followers, [---] engagements


"$BMEA At the 44th Annual J.P. Morgan Healthcare Conference we shared an update on BMF-650 our second clinical-stage asset and an oral GLP-1 receptor agonist for weight loss currently in a Phase I first-in-human study (GLP-131). Learn more: https://investors.biomeafusion.com/ https://investors.biomeafusion.com/"  
[X Link](https://x.com/Biomeainvestors/status/2013701606773051858)  2026-01-20T19:54Z [--] followers, [---] engagements


"$BMEA During the presentation we highlighted preclinical data showing 1215% body-weight reduction in obese primate models with no ALT or AST elevations to date. As BMF-650 advances through dose escalation we remain focused on safety scalability and long-term value"  
[X Link](https://x.com/Biomeainvestors/status/2013701608597553223)  2026-01-20T19:54Z [--] followers, [---] engagements


"$BMEA Diabetes is a complex disease driven by how the body regulates blood sugar. In this video Dr. Biomea explains the role of insulin and pancreatic beta cells and why diabetes often worsens over time. Watch here: https://youtu.be/KQL3RK1a5fQsi=cTXfbMi3wtqahAHM https://youtu.be/KQL3RK1a5fQsi=cTXfbMi3wtqahAHM"  
[X Link](https://x.com/Biomeainvestors/status/2014112883139850709)  2026-01-21T23:08Z [--] followers, [---] engagements


"$BMEA Diabetes develops as beta cells gradually lose their ability to produce enough insulin over time. Dr. Biomea describes how beta cells can become overworked over time leading to reduced insulin production and progressive loss of glucose control. https://youtu.be/oZJgltoNTAosi=g7oQWVxw0FLUjDFv https://youtu.be/oZJgltoNTAosi=g7oQWVxw0FLUjDFv"  
[X Link](https://x.com/Biomeainvestors/status/2016597311787332058)  2026-01-28T19:40Z [--] followers, [---] engagements


"$BMEA This highlights Biomea Fusions focus on understanding the underlying drivers of disease progression and developing treatments that address the root cause of the disease not just the symptoms"  
[X Link](https://x.com/Biomeainvestors/status/2016597313993511088)  2026-01-28T19:40Z [--] followers, [---] engagements


"$BMEA Recent analyst coverage reflects Biomeas clinical stage where value creation is driven by data and milestone execution. With icovamenib in Phase II and BMF-650 in Phase I progress is measured by disciplined development and transparent communication"  
[X Link](https://x.com/Biomeainvestors/status/2016977465395077204)  2026-01-29T20:51Z [--] followers, [---] engagements


"$BMEA Biomea Fusion continues to operate with a focus on financial discipline and efficient clinical development. Based on recent disclosures the companys cash runway extends into [----] supporting planned operating and clinical activities"  
[X Link](https://x.com/Biomeainvestors/status/2018376417881239695)  2026-02-02T17:30Z [--] followers, [---] engagements


"$BMEA This runway supports continued advancement of the Phase II icovamenib program and the Phase I BMF-650 study while maintaining flexibility for upcoming milestones and disciplined capital allocation. Learn more"  
[X Link](https://x.com/Biomeainvestors/status/2018376419672244320)  2026-02-02T17:30Z [--] followers, [---] engagements


"At WCIRDC [----] the discussion focused on patients with Type [--] diabetes driven by loss of insulin-producing beta cells a group where restoring insulin production may change disease progression. 👉 Watch here: https://youtu.be/enom43-T2sYsi=cShkaMu7QuwGTiTR https://youtu.be/enom43-T2sYsi=cShkaMu7QuwGTiTR"  
[X Link](https://x.com/Biomeainvestors/status/2000550936616620540)  2025-12-15T12:58Z [--] followers, [---] engagements


"$BMEA Menin is a natural regulator that limits beta cell growth. By reducing its activity the approach discussed aims to support beta cell recovery and help the body improve its own insulin production rather than relying only on escalating therapy"  
[X Link](https://x.com/Biomeainvestors/status/2000550939858702571)  2025-12-15T12:58Z [--] followers, [---] engagements


"$BMEA The data shared help clarify where a menin focused strategy may have the greatest impact particularly in patients with limited insulin production. As part of our commitment to transparency and engagement we invite the community to share questions ahead of our upcoming AMA"  
[X Link](https://x.com/Biomeainvestors/status/2000550943080034591)  2025-12-15T12:58Z [--] followers, [---] engagements


"At Biomea Fusion $BMEA discovery begins with transparency. Thats why were hosting a new Ask Me Anything welcoming curiosity from anyone who follows our work. Share your questions across our channels. Were listening and we look forward to hearing from you"  
[X Link](https://x.com/Biomeainvestors/status/1996730459124900328)  2025-12-04T23:56Z [--] followers, [---] engagements


"$BMEA At WCIRDC [----] a session highlighted patients whose T2D is driven by loss of insulin-producing beta cells. Biomea Fusions menin-inhibition approach was discussed as a way to support beta-cell recovery. Share your questions for our upcoming AMA. https://youtu.be/08iAqToF93Asi=f7KkupBkTtPbnD3f https://youtu.be/08iAqToF93Asi=f7KkupBkTtPbnD3f"  
[X Link](https://x.com/Biomeainvestors/status/1999199760809386447)  2025-12-11T19:29Z [--] followers, [---] engagements


"$BMEA From the 8th Annual Evercore ISI Healthcare Conference Biomea Fusion discussed menin a protein that limits beta cell growth. COVALENT-111 Week [--] data showed durable insulin production strongest responses in insulin-deficient patients and higher C-peptide levels"  
[X Link](https://x.com/Biomeainvestors/status/1999581035453874290)  2025-12-12T20:44Z [--] followers, [---] engagements


"Biomea Fusion remains focused on advancing this work with scientific clarity and patient need in mind. 👉 Watch here: https://youtu.be/H2n3gfStl7gsi=HW_Un078XG3oVp1n https://youtu.be/H2n3gfStl7gsi=HW_Un078XG3oVp1n"  
[X Link](https://x.com/Biomeainvestors/status/2001689012973769170)  2025-12-18T16:20Z [--] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing